Industrial Technology Research Institute

Zong-Keng Kuo

Chu-Hsun Lu

Shu-Fang Wen

I-Hong Pan

I-Huang Lu

Hui-Ping Tsai

Lain-Tze Lee

I-Horng Pan

Chen-Fang Chung

Jir-Mehng Lo

Kuo-Kuei Huang

Shau-Feng Chang

Kuei-Chang Li

Yen-Wu Hsieh

Yi-Cheng Cheng

Pei-Hsin Lin

Tien-Soung Tong

Meng-Nan Lin

Shu-Jiau Chiou

Hsin-Chieh Wu

Hsin-Jan Yao

Ying-Fei Tsai

Hsiang-Wen Tseng

Mei-Wei Lin

Ching-Huai Ko

Shyh-Horng Lin

Jia-Horng Liaw

Ya-Yan Yang

Chun-Chung Wang

Tze-Chung Lee

Hui-ping Tsai

Tze- Chung Lee

A composition for inhibiting intestinal permeability, treating leaky gut related diseases and/or preventing leaky gut related diseases including a Chinese herbal compound material or a Chinese herbal compound extract is provided. The Chinese herbal compound material includes, red jujube, longan and lotus seed. Moreover, the Chinese herbal compound extract includes aextract, a red jujube extract, a longan extract and a lotus seed extract.

Composition for inhibiting intestinal permeability, treating leaky gut related diseases and/or preventing leaky gut related diseases

A composition for modulating intestinal permeability and/or treating and/or preventing leaky gut related diseases including a Chinese herbal compound material or a Chinese herbal compound extract is provided. The Chinese herbal compound material includes, red jujube, longan and lotus seed. Moreover, the Chinese herbal compound extract includes aextract, a red jujube extract, a longan extract and a lotus seed extract.

Composition for modulating intestinal permeability and/or treating and/or preventing leaky gut related diseases, and method for modulating intestinal permeability and/or treating and/or preventing leaky gut related diseases

A method for treating an autoimmune neurological disease and/or a neurodegenerative disease is provided. The method includes administering an effective amount of at least one compound having Formula (I), Formula (II) or Formula (III), or its geometric isomer, enantiomer or diastereomer to a subject in need thereof: whereinis a single or double bond, X is NCHor CH, Y is null, O or N, Z is O or N, Ris H, OH, and Ris null, H, C-Calkyl, &#x2014;(C&#x2550;O)-alkyl, &#x2014;(C&#x2550;O)-aryl, &#x2014;(C&#x2550;O)-alkyl-aryl, &#x2014;(C&#x2550;O)-heteroaryl, cycloalkyl or heterocycloalkyl, which optionally substituted by one or more of &#x2014;OH, &#x2014;NO, &#x2014;NH, &#x2014;NRR, carbonyl, alkoxyl, alkyl or &#x2014;OCF, wherein Rand Rindependently are H, alkyl, &#x2014;SOCH, &#x2014;(C&#x2550;O)&#x2014;CHor &#x2014;(C&#x2550;O)&#x2014;NH.

Method for treating an autoimmune neurological disease and/or neurodegenerative disease and pharmaceutical formulations for a liquid dosage form and a controlled release dosage form

The present disclosure provides a pharmaceutical composition for treating or alleviating an autoimmune disease and/or complication thereof and/or nephritis, including: an effective amount of an extract of a plant belonging toas an effective ingredient for treating or alleviating the autoimmune disease and/or complication thereof and/or nephritis, wherein the autoimmune disease is selected from a group consisting of lupus erythematosus, psoriasis, psoriatic arthritis, ankylosing spondylitis, rheumatoid arthritis, juvenile idiopathic arthritis, Crohn's disease and ulcerative colitis (UC).

Pharmaceutical composition for treating or alleviating an autoimmune disease and/or complication thereof and/or nephritis and method for treating or alleviating an autoimmune disease and/or complication thereof and/or nephritis

The disclosure provides a pharmaceutical composition for inhibiting angiogenesis, including an effective amount of an extract ofor an effective amount of a lignan as an effective ingredient. The pharmaceutical composition may further include a pharmaceutically acceptable carrier or salt. The disclosure also provides a method for inhibiting angiogenesis, including administering an effective amount of an extract ofor an effective amount of a lignan as an effective ingredient for inhibiting angiogenesis to a subject in need thereof.

Pharmaceutical compositions and method for inhibiting angiogenesis

A pharmaceutical composition for preventing or treating hepatitis C is provided, including oleanolic acid derivatives as an active ingredient and a pharmaceutically acceptable carrier. A method for preventing or treating hepatitis C in a subject in need thereof is also provided by administering the subject the pharmaceutical composition given above.

Pharmaceutical composition and method for preventing or treating hepatitis C

The invention provides an anti-hepatitis C composition including: an effective amount of limonoid compound, wherein the structure of the limonoid compound is shown as Structure (I): where R1 comprises H or OAc and R2 comprises H or COCH(CH); and a pharmaceutically acceptable carrier or salt, and the anti-hepatitis C composition is used for inhibiting hepatitis C virus or treating hepatitis C. The invention also provides a method for treating hepatitis C and a method for preparing a drug for inhibiting hepatitis C viruses or treating hepatitis C.

Anti-hepatitis C composition and method for preparing drug for inhibiting hepatitis C viruses or treating hepatitis C

Growing community of inventors

Taipei, Taiwan

Zong-Keng Kuo